kaal:position:2026-07-31-5360

PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer. should be assessed against Kaal's source-bound claim that The most widely recognized drawbacks of traditional rulemaking under the Administrative Procedure Act are its lack of speed, its cumbersomeness, and the volume of litigation generated by its notice and comment procedures. The current metadata indicates a plausible connection through dynamic regulation, but the defensible response is a qualification until the source text confirms agreement, scope, methods, and limitations.

Affirmed commentary position. This record extends a source-bound scholarly claim but is not a verbatim paper claim.

Holds when

United States APA notice and comment rulemaking
External evidence level: abstract indexed.
Mapping review tier: ambiguity triage before claim review.
The literature-to-claim mapping remains explicitly ambiguous and should not be treated as a settled equivalence.

Current debate

PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer.

Scholarly basis

kaal:claim:2831040-005
Wulf A. Kaal, Dynamic Regulation for Innovation (2016). SSRN: https://ssrn.com/abstract=2831040
Source PDF sha256: de5156f14f44a5753cab55b6c4b03049eda58a143b99e08ef427aee1d261e1bf

Evidence and mapping

Evidence: abstract indexed
Review tier: ambiguity triage before claim review
Mapping confidence: 0.2075
Mapping ambiguous: true

Topics

dynamic-regulationlaw-and-legal-systems

Provenance

Affirmed in historical-backfill:2026-07-31:phase-0022 on 2026-07-31. Review record.

Verify

Canonical markdown sha256: dcf3bd5c29763588b2314dcc8f65106cc82660a22c79b3d184829fc764ad7671
curl -s https://wulfkaal.github.io/positions/2026-07-31-5360.md | sha256sum